Following the flow of the biotech industry, Lava heads to Nasdaq with a gamma delta T cell promise
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
Joining in on the great IPO eruption of the last 12 months, Lava Therapeutics is flowing to Nasdaq.
With a focus on immuno-oncology, the Dutch-American biotech priced late Wednesday night in preparation for a Thursday debut, offering shares initially at $15 apiece. They managed to just eclipse the nine-figure mark, expecting an estimated raise of $100.5 million once the offering closes early next week.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.